🚀 VC round data is live in beta, check it out!
AprilBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for AprilBio and similar public comparables like SSY Group, Mega Lifesciences, Arbutus Biopharma, Cullinan Therapeutics and more.
AprilBio Overview
About AprilBio
AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology.
Founded
2013
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$859M
AprilBio Financials
AprilBio reported last 12-month revenue of $11M and EBITDA of $6M.
In the same LTM period, AprilBio generated $11M in gross profit, $6M in EBITDA, and had net loss of ($13M).
Revenue (LTM)
AprilBio P&L
In the most recent fiscal year, AprilBio reported revenue of $13M and EBITDA of $8M.
AprilBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11M | XXX | $13M | XXX | XXX | XXX |
| Gross Profit | $11M | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 12% | XXX | XXX | XXX |
| EBITDA | $6M | XXX | $8M | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 63% | XXX | XXX | XXX |
| EBIT Margin | 54% | XXX | 63% | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | (112%) | XXX | (52%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AprilBio Stock Performance
AprilBio has current market cap of $921M, and enterprise value of $859M.
Market Cap Evolution
AprilBio's stock price is $40.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $859M | $921M | 0.0% | XXX | XXX | XXX | $-0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAprilBio Valuation Multiples
AprilBio trades at 76.6x EV/Revenue multiple, and 137.6x EV/EBITDA.
EV / Revenue (LTM)
AprilBio Financial Valuation Multiples
As of April 19, 2026, AprilBio has market cap of $921M and EV of $859M.
Equity research analysts estimate AprilBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AprilBio has a P/E ratio of (73.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $921M | XXX | $921M | XXX | XXX | XXX |
| EV (current) | $859M | XXX | $859M | XXX | XXX | XXX |
| EV/Revenue | 76.6x | XXX | 67.5x | XXX | XXX | XXX |
| EV/EBITDA | 137.6x | XXX | 106.8x | XXX | XXX | XXX |
| EV/EBIT | 142.2x | XXX | 106.8x | XXX | XXX | XXX |
| EV/Gross Profit | 76.6x | XXX | 579.5x | XXX | XXX | XXX |
| P/E | (73.4x) | XXX | (138.8x) | XXX | XXX | XXX |
| EV/FCF | 131.9x | XXX | 98.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AprilBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AprilBio Margins & Growth Rates
AprilBio's revenue in the last 12 month declined by (8%).
AprilBio's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
AprilBio's rule of 40 is 442% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AprilBio's rule of X is 1066% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
AprilBio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (8%) | XXX | (40%) | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Growth | (30%) | XXX | (75%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 442% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 1066% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AprilBio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| SSY Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Arbutus Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cullinan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MeiraGTx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AprilBio M&A Activity
AprilBio acquired XXX companies to date.
Last acquisition by AprilBio was on XXXXXXXX, XXXXX. AprilBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AprilBio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAprilBio Investment Activity
AprilBio invested in XXX companies to date.
AprilBio made its latest investment on XXXXXXXX, XXXXX. AprilBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AprilBio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AprilBio
| When was AprilBio founded? | AprilBio was founded in 2013. |
| Where is AprilBio headquartered? | AprilBio is headquartered in South Korea. |
| How many employees does AprilBio have? | As of today, AprilBio has over 26 employees. |
| Is AprilBio publicly listed? | Yes, AprilBio is a public company listed on Korea Exchange. |
| What is the stock symbol of AprilBio? | AprilBio trades under 397030 ticker. |
| When did AprilBio go public? | AprilBio went public in 2022. |
| Who are competitors of AprilBio? | AprilBio main competitors are SSY Group, Mega Lifesciences, Arbutus Biopharma, Cullinan Therapeutics. |
| What is the current market cap of AprilBio? | AprilBio's current market cap is $921M. |
| What is the current revenue of AprilBio? | AprilBio's last 12 months revenue is $11M. |
| What is the current revenue growth of AprilBio? | AprilBio revenue growth (NTM/LTM) is (8%). |
| What is the current EV/Revenue multiple of AprilBio? | Current revenue multiple of AprilBio is 76.6x. |
| Is AprilBio profitable? | Yes, AprilBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AprilBio? | AprilBio's last 12 months EBITDA is $6M. |
| What is AprilBio's EBITDA margin? | AprilBio's last 12 months EBITDA margin is 56%. |
| What is the current EV/EBITDA multiple of AprilBio? | Current EBITDA multiple of AprilBio is 137.6x. |
| What is the current FCF of AprilBio? | AprilBio's last 12 months FCF is $7M. |
| What is AprilBio's FCF margin? | AprilBio's last 12 months FCF margin is 58%. |
| What is the current EV/FCF multiple of AprilBio? | Current FCF multiple of AprilBio is 131.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.